Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13521132 | 1.00 | ALOX5 (0.56) | ALOX5CYP1A2PYCR1MTORSMN1; SMN2 | |
| SCHEMBL25719684 | 1.00 | ALOX5 (0.56) | ALOX5CYP1A2PYCR1MTORSMN1; SMN2 | |
| SCHEMBL13552237 | 0.85 | ALOX5 (0.56) | ALOX5CYP1A2PYCR1MTORSMN1; SMN2 | |
| SCHEMBL23306509 | 0.85 | ALOX5 (0.56) | ALOX5CYP1A2PYCR1MTORSMN1; SMN2 | |
| SCHEMBL12244179 | 0.82 | ALOX5 (0.55) | ALOX5MTORSMN1; SMN2LMNARAB9A | |
| SCHEMBL18945572 | 0.81 | HCRTR1 (0.43) | MTOR | |
| SCHEMBL6413101 | 0.81 | HCRTR1 (0.43) | MTOR | |
| SCHEMBL6512237 | 0.80 | MTOR (0.61) | ALOX5MTOR | |
| SCHEMBL12830195 | 0.80 | MTOR (0.61) | ALOX5MTOR | |
| SCHEMBL12269652 | 0.80 | MTOR (0.61) | ALOX5MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20230391781-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-116916924-A | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4228647-A1 | MALT1 MODULATORS AND USES THEREOF | Rheos Medicines, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081995-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081967-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| CN-101448792-A | Compounds that potentiate AMPA receptors and their use in medicine | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | CN | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391781-A1 | MALT1 MODULATORS AND USES THEREOF | MALT1, SQSTM1, PPP1R10 | ALOX5 3707/4885CYP1A2 3396/4885PYCR1 3189/4885 |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | ALOX5 1225/4885CYP1A2 2601/4885PYCR1 1840/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | ALOX5 1225/4885CYP1A2 2601/4885PYCR1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.